HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 27.53
+1.22 (4.64%)
At close: Jun 18, 2026
HitGen Market Cap
HitGen has a market cap or net worth of 11.03 billion as of June 18, 2026. Its market cap has increased by 74.45% in one year.
Market Cap
11.03B
Enterprise Value
10.30B
Revenue
579.37M
Ranking
n/a
PE Ratio
88.70
Stock Price
27.53
Market Cap Chart
Since April 16, 2020, HitGen's market cap has decreased from 18.86B to 11.03B, a decrease of -41.53%. That is a compound annual growth rate of -8.32%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 18, 2026 | 11.03B | 17.76% |
| Dec 31, 2025 | 9.37B | 90.34% |
| Dec 31, 2024 | 4.92B | -17.81% |
| Dec 29, 2023 | 5.99B | 10.86% |
| Dec 30, 2022 | 5.40B | -42.61% |
| Dec 31, 2021 | 9.41B | -22.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Apr 16, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jinyu Bio-technology | 12.86B |
| Anhui Anke Biotechnology (Group) | 12.79B |
| Mabwell (Shanghai) Bioscience | 11.95B |
| Tibet Cheezheng Tibetan Medicine | 11.12B |
| Inner Mongolia Furui Medical Science | 10.63B |
| Chengzhi | 10.51B |
| Jiangxi Fushine Pharmaceutical | 10.49B |
| Pacific Shuanglin Bio-pharmacy | 10.27B |